Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report

The discovery of epidermal growth factor receptor (EGFR) somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have altered the therapeutic prospects of advanced non-small-cell lung cancer (NSCLC). G719X and S768I are uncommon mutations, and they often exi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Int Med Res
Main Authors: Cai, Yangyang, Wang, Yizhuo, Sun, Jingnan, Wang, Xu, Xu, Yinghui, Sun, Chao, Guo, Ye, Sun, Mengyao, Ma, Kewei
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7273558/
https://ncbi.nlm.nih.gov/pubmed/32493093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060520928793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados